Jagsonpal Pharmaceuticals Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 8, 2025, 1:42 pm

Market Cap	1,462 Cr.
Current Price	220
High / Low	328/108
Stock P/E	40.1
Book Value	29.7
Dividend Yield	0.91 %
ROCE	17.0 %
ROE	13.0 %
Face Value	2.00
PEG Ratio	1.61

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Jagsonpal Pharmaceuticals Ltd

Competitors of Jagsonpal Pharmaceuticals Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
MPS Pharmaa Ltd	6.71 Cr.	3.51	4.33/3.05		0.80	0.00 %	9.15 %	34.9 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	53.1 Cr.	71.5	94.9/32.1	18.0	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	38.0 Cr.	26.0	29.0/8.74	38.8	6.64	0.00 %	2.65 %	2.08 %	10.0
Godavari Drugs Ltd	70.4 Cr.	93.5	155/79.0	11.4	55.4	0.00 %	14.4 %	15.5 %	10.0
Industry Average	17,255.37 Cr	1,081.84		42.42	185.80	0.37%	16.00%	16.32%	6.27

All Competitor Stocks of Jagsonpal Pharmaceuticals Ltd

Quarterly Result

Metric	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Sales	54	51	61	61	60	55	60	58	47	43	61	75	74
Expenses	49	50	53	48	52	50	52	49	44	41	51	58	58
Operating Profit	6	1	7	13	9	5	9	8	3	3	10	16	16
OPM %	10%	2%	12%	21%	14%	10%	14%	14%	7%	6%	17%	22%	21%
Other Income	2	0	-3	1	2	3	2	2	3	2	-2	2	26
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	0	1	0	0	0	0	0	0	0	0	1	2	2
Profit before tax	7	0	4	14	10	7	10	10	5	5	7	15	39
Tax %	24%	32%	24%	24%	21%	24%	26%	25%	25%	22%	25%	25%	17%
Net Profit	5	0	3	10	8	6	7	7	4	4	5	11	32
EPS in Rs	0.83	0.05	0.45	1.59	1.19	0.85	1.14	1.14	0.60	0.54	0.81	1.73	4.82

Last Updated: February 28, 2025, 7:09 pm

Below is a detailed analysis of the quarterly data for Jagsonpal Pharmaceuticals Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

For Sales, as of Dec 2024, the value is ₹74.00 Cr.. The value appears to be declining and may need further review. It has decreased from 75.00 Cr. (Sep 2024) to ₹74.00 Cr., marking a decrease of 1.00 Cr..
For Expenses, as of Dec 2024, the value is ₹58.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 58.00 Cr..
For Operating Profit, as of Dec 2024, the value is ₹16.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 16.00 Cr..
For OPM %, as of Dec 2024, the value is 21.00%. The value appears to be declining and may need further review. It has decreased from 22.00% (Sep 2024) to 21.00%, marking a decrease of 1.00%.
For Other Income, as of Dec 2024, the value is ₹26.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Sep 2024) to ₹26.00 Cr., marking an increase of ₹24.00 Cr..
For Interest, as of Dec 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
For Depreciation, as of Dec 2024, the value is ₹2.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 2.00 Cr..
For Profit before tax, as of Dec 2024, the value is ₹39.00 Cr.. The value appears strong and on an upward trend. It has increased from 15.00 Cr. (Sep 2024) to ₹39.00 Cr., marking an increase of ₹24.00 Cr..
For Tax %, as of Dec 2024, the value is 17.00%. The value appears to be improving (decreasing) as expected. It has decreased from 25.00% (Sep 2024) to 17.00%, marking a decrease of 8.00%.
For Net Profit, as of Dec 2024, the value is ₹32.00 Cr.. The value appears strong and on an upward trend. It has increased from 11.00 Cr. (Sep 2024) to ₹32.00 Cr., marking an increase of ₹21.00 Cr..
For EPS in Rs, as of Dec 2024, the value is 4.82. The value appears strong and on an upward trend. It has increased from ₹1.73 (Sep 2024) to 4.82, marking an increase of ₹3.09.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 3:51 pm

Metric	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	166	144	138	143	144	127	167	159	188	218	237	209	254
Expenses	156	133	129	132	138	138	157	150	169	192	203	186	209
Operating Profit	10	11	9	12	6	-11	9	9	19	26	34	23	45
OPM %	6%	7%	6%	8%	4%	-9%	6%	5%	10%	12%	14%	11%	18%
Other Income	0	0	0	1	13	0	1	3	4	3	2	9	28
Interest	5	5	4	5	3	1	1	1	1	0	0	1	1
Depreciation	3	3	3	3	2	0	1	1	1	2	1	2	6
Profit before tax	3	3	2	4	14	-12	9	9	22	27	35	30	66
Tax %	28%	16%	30%	20%	18%	-1%	20%	16%	22%	29%	23%	25%
Net Profit	2	2	1	3	12	-12	7	8	17	19	27	22	52
EPS in Rs	0.28	0.32	0.18	0.50	1.81	-1.76	1.10	1.20	2.60	2.88	4.08	3.40	7.90
Dividend Payout %	72%	62%	22%	8%	2%	-2%	9%	17%	15%	56%	49%	59%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	0.00%	-50.00%	200.00%	300.00%	-200.00%	158.33%	14.29%	112.50%	11.76%	42.11%	-18.52%
Change in YoY Net Profit Growth (%)	0.00%	-50.00%	250.00%	100.00%	-500.00%	358.33%	-144.05%	98.21%	-100.74%	30.34%	-60.62%

Jagsonpal Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

No data available for the compounded sales growth chart.

Balance Sheet

Last Updated: November 14, 2024, 10:32 pm

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	13	13	13	13	13	13	13	13	13	13	13	13	13
Reserves	85	85	82	85	97	85	91	98	109	120	146	174	184
Borrowings	33	36	39	38	8	8	4	5	7	0	6	9	10
Other Liabilities	21	22	19	22	25	23	28	31	35	31	30	21	51
Total Liabilities	153	156	154	159	143	130	136	147	164	164	195	217	258
Fixed Assets	58	56	52	52	22	21	22	22	26	23	24	9	99
CWIP	2	2	0	0	0	3	4	4	0	0	0	0	0
Investments	0	0	0	0	0	0	0	11	15	51	1	0	0
Other Assets	92	98	102	108	121	105	110	109	123	91	170	208	159
Total Assets	153	156	154	159	143	130	136	147	164	164	195	217	258

Below is a detailed analysis of the balance sheet data for Jagsonpal Pharmaceuticals Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is ₹13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹13.00 Cr..
For Reserves, as of Sep 2024, the value is ₹184.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹174.00 Cr. (Mar 2024) to ₹184.00 Cr., marking an increase of 10.00 Cr..
For Borrowings, as of Sep 2024, the value is ₹10.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from ₹9.00 Cr. (Mar 2024) to ₹10.00 Cr., marking an increase of 1.00 Cr..
For Other Liabilities, as of Sep 2024, the value is ₹51.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹21.00 Cr. (Mar 2024) to ₹51.00 Cr., marking an increase of 30.00 Cr..
For Total Liabilities, as of Sep 2024, the value is ₹258.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹217.00 Cr. (Mar 2024) to ₹258.00 Cr., marking an increase of 41.00 Cr..
For Fixed Assets, as of Sep 2024, the value is ₹99.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹9.00 Cr. (Mar 2024) to ₹99.00 Cr., marking an increase of 90.00 Cr..
For CWIP, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹0.00 Cr..
For Investments, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹0.00 Cr..
For Other Assets, as of Sep 2024, the value is ₹159.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹208.00 Cr. (Mar 2024) to ₹159.00 Cr., marking a decrease of 49.00 Cr..
For Total Assets, as of Sep 2024, the value is ₹258.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹217.00 Cr. (Mar 2024) to ₹258.00 Cr., marking an increase of 41.00 Cr..

Notably, the Reserves (₹184.00 Cr.) exceed the Borrowings (10.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	12	8	4	9	-3	-2	31	11	28	7	47	35
Cash from Investing Activity +	-3	-1	-0	-2	41	-3	-1	-11	-2	-26	-58	-25
Cash from Financing Activity +	-8	-4	-1	-6	-34	-1	-6	-1	-7	-18	-0	-9
Net Cash Flow	0	2	2	1	5	-6	24	-0	19	-36	-11	2

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	-23.00	-25.00	-30.00	-26.00	-2.00	-19.00	5.00	4.00	12.00	26.00	28.00	14.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	93	115	119	106	100	73	45	49	25	26	32	19
Inventory Days	127	173	176	246	295	307	164	191	134	122	82	68
Days Payable	28	29	42	60	56	54	59	76	82	76	66	35
Cash Conversion Cycle	192	259	252	292	339	325	150	164	77	72	48	53
Working Capital Days	130	155	171	169	174	173	76	66	45	59	36	59
ROCE %	6%	6%	5%	7%	3%	-10%	9%	9%	18%	20%	25%	17%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
Promoters	70.34%	70.34%	68.71%	68.71%	68.72%	68.72%	68.72%	68.72%	68.72%	68.48%	68.09%	68.04%
FIIs	0.11%	0.20%	0.00%	0.00%	0.13%	0.11%	0.10%	0.37%	0.38%	0.53%	0.73%	1.10%
DIIs	0.01%	0.00%	0.67%	0.68%	0.28%	0.77%	0.82%	0.82%	0.82%	0.82%	0.84%	0.84%
Public	29.54%	29.46%	30.61%	30.61%	30.85%	30.40%	30.34%	30.07%	30.07%	30.16%	30.33%	30.01%
No. of Shareholders	14,353	20,031	17,100	16,194	14,952	14,535	14,084	13,782	16,041	15,785	16,282	15,748

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
Motilal Oswal S&P BSE Healthcare ETF	83	0.04	0	83	2025-03-06	0%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	5.00	5.00	5.00	5.00	5.00
Basic EPS (Rs.)	8.49	10.20	7.48	6.51	3.00
Diluted EPS (Rs.)	8.46	10.20	7.48	6.51	3.00
Cash EPS (Rs.)	9.13	10.66	8.06	6.71	3.44
Book Value[Excl.RevalReserv]/Share (Rs.)	70.88	60.65	46.96	43.55	39.39
Book Value[Incl.RevalReserv]/Share (Rs.)	70.88	60.65	49.95	46.54	42.38
Dividend / Share (Rs.)	5.00	5.00	4.00	1.00	0.50
Revenue From Operations / Share (Rs.)	78.94	90.36	86.30	71.74	60.53
PBDIT / Share (Rs.)	12.23	15.22	11.12	8.96	4.22
PBIT / Share (Rs.)	11.61	14.76	10.54	8.76	3.79
PBT / Share (Rs.)	11.30	13.29	10.43	8.35	3.59
Net Profit / Share (Rs.)	8.50	10.20	7.48	6.51	3.00
PBDIT Margin (%)	15.49	16.84	12.88	12.48	6.97
PBIT Margin (%)	14.70	16.34	12.20	12.21	6.26
PBT Margin (%)	14.31	14.70	12.08	11.63	5.93
Net Profit Margin (%)	10.76	11.28	8.66	9.07	4.96
Return on Networth / Equity (%)	11.98	16.81	15.92	14.95	7.62
Return on Capital Employeed (%)	15.50	23.10	20.55	18.54	8.69
Return On Assets (%)	10.34	13.70	11.62	10.38	5.35
Total Debt / Equity (X)	0.00	0.00	0.00	0.05	0.04
Asset Turnover Ratio (%)	1.01	1.30	1.36	1.21	1.12
Current Ratio (X)	10.42	5.97	3.24	2.98	2.89
Quick Ratio (X)	9.63	5.22	2.37	2.25	2.00
Inventory Turnover Ratio (X)	1.24	1.24	1.36	1.31	1.19
Dividend Payout Ratio (NP) (%)	58.31	0.00	53.50	15.35	16.64
Dividend Payout Ratio (CP) (%)	54.29	0.00	49.63	14.91	14.55
Earning Retention Ratio (%)	41.69	0.00	46.50	84.65	83.36
Cash Earning Retention Ratio (%)	45.71	0.00	50.37	85.09	85.45
Interest Coverage Ratio (X)	39.74	96.57	102.18	21.61	21.51
Interest Coverage Ratio (Post Tax) (X)	28.60	74.08	69.70	16.71	16.31
Enterprise Value (Cr.)	591.93	644.85	795.42	154.96	12.31
EV / Net Operating Revenue (X)	2.84	2.72	3.52	0.82	0.07
EV / EBITDA (X)	18.30	16.17	27.31	6.60	1.11
MarketCap / Net Operating Revenue (X)	3.54	3.21	3.63	1.11	0.28
Retention Ratios (%)	41.68	0.00	46.49	84.64	83.35
Price / BV (X)	3.95	4.78	6.68	1.83	0.44
Price / Net Operating Revenue (X)	3.54	3.21	3.63	1.11	0.28
EarningsYield	0.03	0.03	0.02	0.08	0.17

After reviewing the key financial ratios for Jagsonpal Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 5.00.
For Basic EPS (Rs.), as of Mar 24, the value is 8.49. This value is within the healthy range. It has decreased from 10.20 (Mar 23) to 8.49, marking a decrease of 1.71.
For Diluted EPS (Rs.), as of Mar 24, the value is 8.46. This value is within the healthy range. It has decreased from 10.20 (Mar 23) to 8.46, marking a decrease of 1.74.
For Cash EPS (Rs.), as of Mar 24, the value is 9.13. This value is within the healthy range. It has decreased from 10.66 (Mar 23) to 9.13, marking a decrease of 1.53.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 70.88. It has increased from 60.65 (Mar 23) to 70.88, marking an increase of 10.23.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 70.88. It has increased from 60.65 (Mar 23) to 70.88, marking an increase of 10.23.
For Dividend / Share (Rs.), as of Mar 24, the value is 5.00. This value exceeds the healthy maximum of 3. There is no change compared to the previous period (Mar 23) which recorded 5.00.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 78.94. It has decreased from 90.36 (Mar 23) to 78.94, marking a decrease of 11.42.
For PBDIT / Share (Rs.), as of Mar 24, the value is 12.23. This value is within the healthy range. It has decreased from 15.22 (Mar 23) to 12.23, marking a decrease of 2.99.
For PBIT / Share (Rs.), as of Mar 24, the value is 11.61. This value is within the healthy range. It has decreased from 14.76 (Mar 23) to 11.61, marking a decrease of 3.15.
For PBT / Share (Rs.), as of Mar 24, the value is 11.30. This value is within the healthy range. It has decreased from 13.29 (Mar 23) to 11.30, marking a decrease of 1.99.
For Net Profit / Share (Rs.), as of Mar 24, the value is 8.50. This value is within the healthy range. It has decreased from 10.20 (Mar 23) to 8.50, marking a decrease of 1.70.
For PBDIT Margin (%), as of Mar 24, the value is 15.49. This value is within the healthy range. It has decreased from 16.84 (Mar 23) to 15.49, marking a decrease of 1.35.
For PBIT Margin (%), as of Mar 24, the value is 14.70. This value is within the healthy range. It has decreased from 16.34 (Mar 23) to 14.70, marking a decrease of 1.64.
For PBT Margin (%), as of Mar 24, the value is 14.31. This value is within the healthy range. It has decreased from 14.70 (Mar 23) to 14.31, marking a decrease of 0.39.
For Net Profit Margin (%), as of Mar 24, the value is 10.76. This value exceeds the healthy maximum of 10. It has decreased from 11.28 (Mar 23) to 10.76, marking a decrease of 0.52.
For Return on Networth / Equity (%), as of Mar 24, the value is 11.98. This value is below the healthy minimum of 15. It has decreased from 16.81 (Mar 23) to 11.98, marking a decrease of 4.83.
For Return on Capital Employeed (%), as of Mar 24, the value is 15.50. This value is within the healthy range. It has decreased from 23.10 (Mar 23) to 15.50, marking a decrease of 7.60.
For Return On Assets (%), as of Mar 24, the value is 10.34. This value is within the healthy range. It has decreased from 13.70 (Mar 23) to 10.34, marking a decrease of 3.36.
For Total Debt / Equity (X), as of Mar 24, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 0.00.
For Asset Turnover Ratio (%), as of Mar 24, the value is 1.01. It has decreased from 1.30 (Mar 23) to 1.01, marking a decrease of 0.29.
For Current Ratio (X), as of Mar 24, the value is 10.42. This value exceeds the healthy maximum of 3. It has increased from 5.97 (Mar 23) to 10.42, marking an increase of 4.45.
For Quick Ratio (X), as of Mar 24, the value is 9.63. This value exceeds the healthy maximum of 2. It has increased from 5.22 (Mar 23) to 9.63, marking an increase of 4.41.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.24. This value is below the healthy minimum of 4. There is no change compared to the previous period (Mar 23) which recorded 1.24.
For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 58.31. This value exceeds the healthy maximum of 50. It has increased from 0.00 (Mar 23) to 58.31, marking an increase of 58.31.
For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 54.29. This value exceeds the healthy maximum of 50. It has increased from 0.00 (Mar 23) to 54.29, marking an increase of 54.29.
For Earning Retention Ratio (%), as of Mar 24, the value is 41.69. This value is within the healthy range. It has increased from 0.00 (Mar 23) to 41.69, marking an increase of 41.69.
For Cash Earning Retention Ratio (%), as of Mar 24, the value is 45.71. This value is within the healthy range. It has increased from 0.00 (Mar 23) to 45.71, marking an increase of 45.71.
For Interest Coverage Ratio (X), as of Mar 24, the value is 39.74. This value is within the healthy range. It has decreased from 96.57 (Mar 23) to 39.74, marking a decrease of 56.83.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 28.60. This value is within the healthy range. It has decreased from 74.08 (Mar 23) to 28.60, marking a decrease of 45.48.
For Enterprise Value (Cr.), as of Mar 24, the value is 591.93. It has decreased from 644.85 (Mar 23) to 591.93, marking a decrease of 52.92.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 2.84. This value is within the healthy range. It has increased from 2.72 (Mar 23) to 2.84, marking an increase of 0.12.
For EV / EBITDA (X), as of Mar 24, the value is 18.30. This value exceeds the healthy maximum of 15. It has increased from 16.17 (Mar 23) to 18.30, marking an increase of 2.13.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 3.54. This value exceeds the healthy maximum of 3. It has increased from 3.21 (Mar 23) to 3.54, marking an increase of 0.33.
For Retention Ratios (%), as of Mar 24, the value is 41.68. This value is within the healthy range. It has increased from 0.00 (Mar 23) to 41.68, marking an increase of 41.68.
For Price / BV (X), as of Mar 24, the value is 3.95. This value exceeds the healthy maximum of 3. It has decreased from 4.78 (Mar 23) to 3.95, marking a decrease of 0.83.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 3.54. This value exceeds the healthy maximum of 3. It has increased from 3.21 (Mar 23) to 3.54, marking an increase of 0.33.
For EarningsYield, as of Mar 24, the value is 0.03. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 23) which recorded 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Jagsonpal Pharmaceuticals Ltd as of March 12, 2025 is: ₹124.99

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, Jagsonpal Pharmaceuticals Ltd is Overvalued by 43.19% compared to the current share price 220.00

Intrinsic Value of Jagsonpal Pharmaceuticals Ltd as of March 12, 2025 is: 156.10

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, Jagsonpal Pharmaceuticals Ltd is Overvalued by 29.05% compared to the current share price 220.00

Last 5 Year EPS CAGR: 24.89%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The company has higher reserves (110.85 cr) compared to borrowings (15.62 cr), indicating strong financial stability. The company has shown consistent growth in sales (176.46 cr) and profit (16.31 cr) over the years.	The stock has a low average ROCE of 9.58%, which may not be favorable. The stock has a high average Working Capital Days of 109.42, which may not be favorable. The stock has a high average Cash Conversion Cycle of 185.25, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Jagsonpal Pharmaceuticals Ltd:
1. Net Profit Margin: 10.76%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 15.5% (Industry Average ROCE: 16%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 11.98% (Industry Average ROE: 16.32%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 28.6
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 9.63
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 40.1 (Industry average Stock P/E: 42.42)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Jagsonpal Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 17/08/1978 and has its registered office in the State of Delhi, India. Company's Corporate Identification Number(CIN) is L74899DL1978PLC009181 and registration number is 009181. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 208.70 Cr. and Equity Capital is Rs. 13.22 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	T-210 J, Shahpur Jat, New Delhi Delhi 110049	cs@jagsonpal.com http://www.jagsonpal.com

Management
Name	Position Held
Mr. Rajpal Singh Kochhar	Chairman Emeritus
Mr. Harsha Raghavan	Chairman & Non-Exe.Director
Mr. Manish Gupta	Managing Director
Mr. Prithipal Singh Kochhar	Non Executive Director
Mr. Debasis Bikash Nandy	Independent Director
Ms. Radhika Madhukar Dudhat	Independent Director
Ms. Pallavi Dinodia Gupta	Independent Director

FAQ

What is the latest intrinsic value of Jagsonpal Pharmaceuticals Ltd?

The latest intrinsic value of Jagsonpal Pharmaceuticals Ltd as on 12 March 2025 is ₹124.99, which is 43.19% lower than the current market price of 220.00, indicating the stock is overvalued by 43.19%. The intrinsic value of Jagsonpal Pharmaceuticals Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹1,462 Cr. and recorded a high/low of ₹328/108 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹184 Cr and total liabilities of ₹258 Cr.

What is the Market Cap of Jagsonpal Pharmaceuticals Ltd?

The Market Cap of Jagsonpal Pharmaceuticals Ltd is 1,462 Cr..

What is the current Stock Price of Jagsonpal Pharmaceuticals Ltd as on 12 March 2025?

The current stock price of Jagsonpal Pharmaceuticals Ltd as on 12 March 2025 is ₹220.

What is the High / Low of Jagsonpal Pharmaceuticals Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Jagsonpal Pharmaceuticals Ltd stocks is ₹328/108.

What is the Stock P/E of Jagsonpal Pharmaceuticals Ltd?

The Stock P/E of Jagsonpal Pharmaceuticals Ltd is 40.1.

What is the Book Value of Jagsonpal Pharmaceuticals Ltd?

The Book Value of Jagsonpal Pharmaceuticals Ltd is 29.7.

What is the Dividend Yield of Jagsonpal Pharmaceuticals Ltd?

The Dividend Yield of Jagsonpal Pharmaceuticals Ltd is 0.91 %.

What is the ROCE of Jagsonpal Pharmaceuticals Ltd?

The ROCE of Jagsonpal Pharmaceuticals Ltd is 17.0 %.

What is the ROE of Jagsonpal Pharmaceuticals Ltd?

The ROE of Jagsonpal Pharmaceuticals Ltd is 13.0 %.

What is the Face Value of Jagsonpal Pharmaceuticals Ltd?

The Face Value of Jagsonpal Pharmaceuticals Ltd is 2.00.